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The green chemistry approach provides for the synthesis of coumarin-1,4-dihydropyridine scaffolds 6a-o via sequential 
multicomponent reaction using catalytic amount of triethylamine (TEA). These new coumarin scaffolds have been 
successfully explored for the effective inflammatory as well as microbial infection inhibitors. The antimicrobial activity 
results of the title compounds have shown potent activity against both gram positive and gram negative bacterial, and fungal 
stains. Additionally, anti-inflammatory activity of all the compounds has been found to be quite promising in comparison 
with standard Diclofenac sodium. Furthermore, the in silico docking study has been performed for all the compounds with S. 
aureus DNA gyrase and cyclooxygenase-2 (PDB ID 4PH9). The computational results are in good agreement with the 
in vitro antibacterial and anti-inflammatory experimental results. 
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green protocol 
Green chemistry an approach to prevent the pollution 
during the synthesis of chemical products provides 
environment friendly protocols to the 
pharmaceuticals1. On other hand one pot sequential 
multicomponent reactions have improved efficiency 
of multiple bond formation makes atom economy, 
energy, time saving, avoiding waste and pollution are 
the major contributions to the field of green 
chemistry, so it has become an important area of 
research in organic chemistry2-5. 
In medicinal chemistry, the synthesis of bioactive 
heterocycles is the challenging goal. While, 
heterocyclic skeletons are the attractive framework 
for synthetic organic chemist6. Among various 
heterocycles, pyridine and their hydrogenated 
derivatives are more significant, possessing diverse 
biological activities and found in naturally occurring 
compounds. Dihydropyridine nucleus is the most 
attractive structural framework present in many drugs 
and pharmaceuticals7,8. Dihydropyridine nucleus 
containing molecules reveal various biological 
activities like, antimicrobial9, anti-inflammatory10, 
anticancer11, antioxidant12, anti-hypertension13 and in 
pharmacology as calcium channel blockers14. The 
commercially available dihydropyridine nucleus 
having drug molecules such as, Felodipine, 
Amlodipine, Nifedipine and Nimodipine (Figure 1) 
are used for the treatment of cardiac disease, 
hypertension, angina pectoris and congestive heart 
failure15,16. This remarkable drug activity of 
dihydropyridines (DHP’s) attracted many chemists 
and has become interesting research area17. 
Coumarin nucleus having scaffolds are well cited 
in literature due to their pronounced anti-
inflammatory activity18 and the structural 
modification on coumarin nucleus have showed 
influenced antimicrobial activity19. Design concept of 
the present scaffolds are derived from our earlier 
work on coumarinyldihydropyrimidinones (Figure 1, 
C), they exhibited promising antimicrobial and anti-
inflammatory activity20,21. Attention has made both 
heterocycles towards various biological activities, 
hence much microbial infection has been treating with 
antibiotics and these antibiotics also served as anti-




inflammatory agents22. Therefore, the above 
mentioned results and our continuation efforts have 
made to synthesize more potent and less toxic new 
candidates of antimicrobial and anti-inflammatory 
agents by multicomponent reaction using green 
chemical techniques. The present report gives an 
account for the synthesis of coumarin substituted 1,4-
dihydropyridine derivatives (Figure 1, D) and their 
biological screening studies such as antimicrobial, 
anti-inflammatory and molecular docking study. 
 
Results and Discussion 
 
Chemistry 
We describe here the design and synthesis of new 
coumarin-1, 4-dihydropyridine scaffolds (6) 
represented in Scheme I. Initially, the required 
substituted 4-formylcoumarin (2)23 was synthesized 
from 4-bromomethylcoumarin24. Further, the target 
compound 6 was obtained using compound 2 via one 
pot multicomponent approach under ecofriendly 
condition. 
Our attempt was to synthesize the target compound 
(6) by one pot multicomponent reaction (MCRs) under 
green protocol taking 6-methyl-4-formylcoumarin (2), 
aniline (3), dimethyl acetylene dicarboxylate (DMAD) 
(4) and malononitrile (5) as model example in basic 
condition at room temperature (RT). Initially, four 
component reaction was performed using TEA as base 
in ethanol at RT for 24 h, this reaction resulted very poor 
yield of desired product 6 along with identified two 
major products such as Schiff base (7) and coumarinyl 
malononitrile (8) (Entry 1, Table I). Further, in order to 
obtain desired product 6 in good yield at optimized 
reaction condition, a series of experiments were 
performed using different base, but results are not 
satisfactory (Entry 2 to 4, Table I). By examining the 
above reaction, we thought of modifying the reaction 
condition in terms of addition of reagents sequentially 
 
 




Scheme I — Synthesis of coumarin-1,4-dihydropyridine derivatives 6a-o 




instead of mixing all the reagents at once. The 
performed reaction by taking aniline (3) and DMAD (4) 
in ethanol stirred at RT for 10 min, in this ethanolic 
solution 4-formylcoumarin (2), malononitrile (5) and 
TEA was added and stirred for about 8-10 h, in this 
method we noticed the desired product 6 with improved 
yield (Entry 5, Table I). Moreover, to get better yield, 
additional optimization was carried out using different 
base, but not much progress was observed in the yield 
(Entry 6 and 7, Table I). From the above discussed 
conditions, we noticed that a 30-35% starting material 
remains in the reaction, due to benzaldehyde reacts with 
malononitrile and aniline to lead corresponding 
identified intermediates 7 and 8 respectively. In order to 
increase the reactivity of aniline (3) and DMAD (4) we 
performed reaction by mixing DMAD (4) and aniline (3) 
without solvent at RT under stirring for 3 to 4 h. 
Meanwhile, 4-formylcoumarin (2), malononitrile (5) 
with catalytic amount of TEA in ethanol was prepared 
under stirring for 7 h. The separately prepared reaction 
mixture was mixed and stirred for 1h. Surprisingly, 
under this condition, we obtained the desired product in 
excellent yield (Entry 8, Table I). Using this standard 
protocol, different substituted coumarin-1,4-
dihydropyridine scaffolds were synthesized in good 
yield. The lists of synthesized compounds are given in 
Figure 2. 
Plausible reaction mechanism is given in 
Scheme II. Firstly, the aza-Michael addition takes 
place between DMAD (4) and substituted aryl amines 
(3) to produce the intermediate A, this is rate 
determining step. Next, catalytic amount of 
triethylamine act as a base to induce the Knoevenagel 
condensation reaction between 4-formylcoumarin (2), 
malononitrile (5) providing the compound 8. Further, 
by adding intermediate A and 8, Michael addition 
take place to form the adduct B, then B transferred to 
C by the shift of proton. The intermediate C further 
undergoes intramolecular cyclization with nitrile 
carbon to form intermediate D and led the targeted 
product coumarin-1, 4-dihydropyridineby 
tautomerization of imino group to amino group. 
In case of compound 6a the IR shows NH2 
asymmetric and symmetric stretching bands at 3423 
and 3367 cm−1 respectively. The nitrile stretching 
band exhibited at 2180 cm−1 and stretching bands of 
ester carbonyl group of dihydropyridine and lactone 
carbonyl group of coumarin are observed at 1753 and 
1712 cm−1 respectively. Compound 6a was confirmed 
by the GC-MS, which shows mass at m/z 471 
correspond to the molecular ion peak of compound. 
Further, 1H NMR spectral data supports the formation 
of compound 6a, the three singlets were resonated at δ 
2.45, δ 3.51 and δ 3.41 corresponds to methyl group 
of coumarin and two ester methyl group of 
dihydropyridine respectively. The two singlets 
resonated at δ 5.87 and δ 5.18 are due to NH2 and 
methine protons of dihydropyridine respectively. 
Coumarin C3-H appeared as a singlet at δ 6.20 and 
C7H of coumarin resonated as doublet at δ 7.55 
(J=8Hz) and C5-H of coumarin resonated as a singlet 
at δ 7.46. C8-H of coumarin resonated as doublet at δ 





























Entry Catalyst Solvent Condition Time (h) Yield (6a) (%) Yield (7) (%) Yield (8) (%) 
1 TEA Ethanol RT 24 10 18 37 
2 K2CO3 Ethanol RT 24 7 17 35 
3 Piperidine Ethanol RT 24 5 12 27 
4 DBU Ethanol RT 24 5 15 25 
5 TEA Ethanol RT 12 38 12 23 
6 Piperidine Ethanol RT 12 22 7 16 
7 DBU Ethanol RT 12 18 5 12 
8 TEA (Ethanol) RT 12 87 − 5 




8.07 (J=8Hz) and phenyl proton appeared as a 
multiplet in the region δ 7.32 respectively. 
Biological screening 
In vitro antibacterial study 
Novel coumarin-1,4-dihydropyridine derivatives 
6(a-o) were assessed for their in vitro antibacterial 
activity against Gram positive bacterial strains S. 
aureus, B. subtilis and Gram-negative bacterial strains 
E. coli and P. aeruginosa respectively. Whereas, two 
references drugs gentamycin and ampicillin were used 
 
 




Scheme II — Plausible mechanism for the synthesis of coumarin substituted 1, 4-dihydropyridine derivatives 6a-o 




and determined the minimum inhibitory concentration 
(MIC) of all the compounds, the antibacterial MIC 
results of all the compounds are tabulated in Table II. 
Antibacterial activity results of all the targeted 
compounds reveals that; most of the compounds 6(a-o) 
are exhibiting low activity. Compounds 6a (C6-CH3 
substitution on coumarin) and 6e (C7-CH3 substitution 
on coumarin and C3,C4-di-CH3 on phenyl ring) are 
found to be encourageable antibacterial agents against 
Gram positive S.aureus and B.subtilis bacterial strain 
with MIC 32 μM/mL which shows equipotent activity 
with standard drug Gentamycin (32 μM/mL). Further, 
compounds 6c (C6-CH3 substitution on coumarin and 
C4-Cl on phenyl ring), 6h (C6-OCH3 on coumarin and 
C3, C4-di-CH3 substitution on phenyl ring) and 6n (7,8-
benzo substitution on coumarin and C3, C4-di-CH3 on 
phenyl ring) showed good activity against both Gram 
positive bacterial strains with MIC value ranging 32-64 
μM/mL over the standard drug Gentamycin (32 
μM/mL) and found to be least active compared with 
standard drugAmpicillin (MIC=8 and 4 μM/mL) 
respectively. Wherein, other compounds showed 
moderate activity. Moreover, the results showed that, 
all synthesized compounds are less active against both 
gram –ve bacterial strains. The activity results of all 
compounds are represented in Figure 3. 
From the above discussion, antibacterial activity of all 
compounds reveals that, coumarin dihydropyridines 
having H, C3, C4-di-CH3 substitution on phenyl ring are 
found to be promising antibacterial agents. Most of the 
compounds having C4-Cl on phenyl ring showed 
moderate activity. The novel coumarin-1,4-
dihydropyridines are considered to be promising 
structural templates for the development of more 
efficient antibacterial agent in future. 
 
In vitro antifungal study 
In vitro antifungal activity results of all newly 
synthesized scaffolds are summarized in Table III. 
Minimum inhibitory concentration (MIC) value of all 
compounds against two fungal stains C. albicans and 
A. nigerwere determinedtheMIC measured in μM/mL 
using Amphotericin-B as standard drug. 
Table III reveals that, most of the compounds are 
less active against both fungal strains compared to 
Table II — In vitro antibacterial activity of coumarin-1,4-dihydropyridine derivatives 6a-o 
Compd R R1 Minimum inhibitory concentrations (MIC) in μM/mL 
Gram positive Gram negative 
B. subtilis S. aureus P. aeruginosa E. coli 
6a 6-CH3 H 32 32 ≥256 ≥256 
6b 6-CH3 3,4-di-CH3 ≥256 ≥256 64 ≥256 
6c 6-CH3 4-Cl 64 32 ≥256 64 
6d 7-CH3 H ≥256 64 ≥256 ≥256 
6e 7-CH3 3,4-di-CH3 32 32 64 ≥256 
6f 7-CH3 4-Cl ≥256 ≥256 ≥256 128 
6g 6-OCH3 H 128 ≥256 64 128 
6h 6-OCH3 3,4-di-CH3 64 64 64 ≥256 
6i 6-OCH3 4-Cl ≥256 ≥256 ≥256 128 
6j 5,6-Benzo H ≥256 ≥256 ≥256 ≥256 
6k 5,6-Benzo 3,4-di-CH3 128 32 128 64 
6l 5,6-Benzo 4-Cl ≥256 64 ≥256 ≥256 
6m 7,8-Benzo H ≥256 128 ≥256 64 
6n 7,8-Benzo 3,4-di-CH3 64 32 ≥256 ≥256 
6o 7,8-Benzo 4-Cl ≥256 ≥256 128 64 
Gentamycin   32 32 8 16 
Ampicillin   8 4 16 32 
 
Figure 3 — Graphical representation of all the compounds
minimum inhibitory concentration (MIC) (μM/mL) against
B.subtilis, S.aureus, P.aeruginosa and E.coli. 




standard drug molecules. Among all compounds, 6e 
(C7-CH3 substitution on coumarin and C3,C4-di-CH3 
substitution on phenyl ring) and 6j (5,6-benzo 
substitution on coumarin) have showed activity 
towards both fungi C. albicans and A. niger with MIC 
64 μM/mL. 
From the results, we observe that, dihydropyridines 
with C4-Cl substitution on phenyl ring shows least 
activity against both fungal strains compared to other 
substitution on phenyl ring. Different substitution on 
coumarin nucleus and phenyl ring has not shown 
much effects on the fungal strains. Figure 4 shows 
graphical representation of minimum inhibitory 
concentration of all the compounds. 
 
In vitro anti-inflammatory study 
In vitro anti-inflammatory activity evaluation of 
title compounds was determined by egg albumin 
denaturation method using Diclofenac sodium as a 
standard, the results obtained are presented in 
Table IV. Figure 5 shows the percentage inhibition of 
all the compounds, which showed remarkable activity 
against denaturation of protein over standard 
Diclofenac sodium. Compound 6i (C6-OCH3 
substitution on coumarin and C4-Cl on phenyl ring) 
shows highest inhibition (89.33%), whereas, 6c (C6-
CH3 substitution on coumarin and C4-Cl on phenyl 
ring) shows least inhibition (39.33%) compared with 
standard Diclofenac sodium. While, compounds 6d 
(C7-CH3 on coumarin), 6e (C7-CH3 on coumarin and 
C3, C4-di-CH3 on phenyl ring), 6g (C6-OCH3 on 
coumarin and C4-OCH3 on phenyl ring), 6h (C6-OCH3 
on coumarin and phenyl ring), 6n (7, 8-benzo on 
coumarin and C3,C4-di-CH3 on phenyl ring), 6k (5,6-
benzo on coumarin and C3,C4-di-CH3 on phenyl ring) 
and 6m (7,8-benzo on coumarin and phenyl ring, 
C3,C4-di-CH3 on phenyl ring) shows good activity 
with inhibition range from 74.16-85.26%. Further, 
compounds 6a, 6b, 6c, 6f, 6j, 6l and 6o showed least 
activity with inhibition ranges from 39.33-70.00%. 
From the above discussion we observe that, 
compounds with C6-OCH3 substitution on coumarin 
exhibited good anti-inflammatory activity with 
maximum inhibition range from 82.16-89.33%. 
Whereas, compounds having C6-CH3 substitution on 
coumarin and C4-Cl substitution on phenyl ring are 




Figure 4 — Graphical representation of minimum inhibitory
concentration (MIC) (μM/mL) against C. albicans and A. niger. 
Table III — In vitro antifungal activity of coumarin-1,4-dihydropyridine derivatives 6a-o 
Compd R R1 Minimum Inhibitory Concentrations (MIC) in μM/mL 
C. albicans A. niger 
6a 6-CH3 H ≥256 128 
6b 6-CH3 3,4-di-CH3 128 ≥256 
6c 6-CH3 4-Cl ≥256 ≥256 
6d 7-CH3 H 64 128 
6e 7-CH3 3,4-di-CH3 64 64 
6f 7-CH3 4-Cl ≥256 128 
6g 6-OCH3 4-OCH3 64 ≥256 
6h 6-OCH3 3,4-di-CH3 ≥256 128 
6i 6-OCH3 4-Cl 128 ≥256 
6j 5,6-Benzo H 64 64 
6k 5,6-Benzo 3,4-di-CH3 128 64 
6l 5,6-Benzo 4-Cl ≥256 ≥256 
6m 7,8-Benzo H 64 128 
6n 7,8-Benzo 3,4-di-CH3 ≥256 128 
6o 7,8-Benzo 4-Cl ≥256 ≥256 
Amphotericin-B   4 ≥2 





To demonstrate the mechanism of antibacterial 
activity and information of intermolecular interactions 
of the synthesized scaffold, we performed molecular 
docking studies on the crystal structure of twinned 
3.35A structure of S. aureus Gyrase complex with 
ciprofloxacin and DNA (PDB ID: 2XCT) using the 
surflex-dock programme of sybyl-X 2.0 software. All 
the synthesized 15 inhibitors were docked into the 
active site of enzyme and the identified binding 
energies of the targets are listed in supplementary file 
(Fig. S4 Table S1). The docking study revealed that 
all the compounds have exhibited good docking score. 
As presented in Figure 6, the compound 6a makes 
four hydrogen bonding interactions at the active site 
of the enzyme (PDB ID: 2XCT). The oxygen atoms 
of carboxylate group present at the 3rd position of 
dihydropyridine ring makes two hydrogen bonding 
interactions with hydrogen’s of U/SER1084 (O···H-
U/SER1084, 1.75 Å and 2.74 Å). Oxygen atom 
present in the coumarin ring makes a hydrogen 
bonding interaction with hydrogen of W/DA7 (O H-
W/DA7, 2.74 Å) and remaining hydrogen bonding 
interaction raised from the hydrogen atom of amino 
group present on the 6th position of dihydropyridine 
ring with nitrogen of W/DG8 (NH N-W/DG8,  
2.47 Å) amino acid residue respectively. 
The insilico study of reference drug ciprofloxacin 
was also performed to camper the synthesized 
compounds interaction with enzymes. Figure 7 has 
shown interactions between ciprofloxacin and 
enzyme. Ciprofloxacin showed four intermolecular 
hydrogen bonding interactions at the active site of the 
enzyme (PDB ID: 2XCT). The C4 carbonyl oxygen of 
quinoline makes hydrogen bonding interaction with 
hydrogen of X/DC12 (C=O H-X/DC12, 2.33 Å) 
amino acid residue and carboxylic acid oxygen atom 
of carbonyl group makes hydrogen bonding 
interaction with hydrogen of X/DC12 (C=O H-
X/DC12, 2.69 Å) respectively. Whereas, oxygen atom 
of hydroxyl group of carboxylic acid raises one 
bonding interaction with hydrogen of X/DC13 
(C=O H-X/DC13, 1.89 Å) and remaining one 
bonding interaction raised from the hydrogen atom of 
NH of piperazine ring with oxygen of Y/DG9 
(NH H-Y/DG9, 1.93 Å). The hydrophobic and 
hydrophilic interaction of scaffolds 6a and 6d are 
presented in Figure 8. 
Table IV — In vitro anti-inflammatory activity results of coumarin-1,4-dihydropyridine derivatives 6a-o 
Compd R R1 % Inhibition of egg albumin in 100 μg/mL 
6a 6-CH3 H 44.0000±0.57735 
6b 6-CH3 3,4-di-CH3 52.0000±0.57735 
6c 6-CH3 4-Cl 39.3333±0.57735 
6d 7-CH3 H 74.1633±0.58081 
6e 7-CH3 3,4-di-CH3 79.5233±0.39431 
6f 7-CH3 4-Cl 58.3333±0.88192 
6g 6-OCH3 4-OCH3 82.1633±0.58081 
6h 6-OCH3 3,4-di-CH3 86.0000±0.57735 
6i 6-OCH3 4-Cl 89.3333±0.88192 
6j 5,6-Benzo H 70.0000±0.57735 
6k 5,6-Benzo 3,4-di-CH3 79.1200±0.67735 
6l 5,6-Benzo 4-Cl 69.0000±0.57735 
6m 7,8-Benzo H 75.1253±0.52318 
6n 7,8-Benzo 3,4-di-CH3 85.2634±0.49829 
6o 7,8-Benzo 4-Cl 68.0000±0.57735 
Diclofenac Sodium   94.3867±0.63980 
 
 
Figure 5 — Graphical representation of % inhibition of egg 
albuminin100 μg/mL for compounds 6a-o 




To demonstrate the mechanism of anti-
inflammatory activity and its possible intermolecular 
interactions information between the targets and 
enzymes, the molecular docking study was performed 
on the crystal structure of ibuprofen bound to 
cyclooxygenase-2 (PDB ID 4PH9) using the surflex-
dock programme of sybyl-X 2.0 software. All the 
synthesized fifteen inhibitors were docked into the 
active site of enzyme and the obtained binding 
energies of the targets are listed in supplementary file 
(Figure S6, Table S2). Computational study revealed 
that all the compounds have exhibited very good 
docking score. 
As presented in the Figure 9 (A-C), compound 6d, 
makes four bonding interactions at the active site of 
the enzyme (PDB ID: 4PH9). The oxygen atom of 
carboxylate group present at the 3rd position of 
dihydropyridine ring makes a hydrogen bonding 
interaction with hydrogen atom of SER354 (C=O----
H-SER354, 2.54 Å) amino acid residue, coumarin 
ring oxygen atom makes a hydrogen bonding 
interaction with hydrogen atom of TYR356 (O----H-
TYR356, 2.594 Å) amino acid residue and remaining 
tow hydrogen bonding interactions raised from the 
oxygen atom of carbonyl group of coumarin ring and 
hydrogen atoms of ARG121 and TYR356 (C=O-----
H-ARG121, 2.04 Å, C=O-----H-TYR356, 2.59 Å) 
amino acid residues respectively. 
The comparative molecular docking study results of 
synthesized compounds and reference drug Ibuprofen 
noticed that the synthesized compounds exhibited high 
C-score value. The synthesized scaffolds bind to the 
active site of enzyme is similar to that of Ibuprofen. 
Interestingly, the synthesized scaffolds have same H-
bonding interactions with same amino acids ARG121 
and TYR356 as that of Ibuprofen. 
 
 
Figure 6 — Docked view of compound 6a at the active site of the enzyme (PDB ID: 2XCT) 




As depicted in the Figure 10 (A-C), Ibuprofen, 
makes four hydrogen bonding interactions at the 




Materials and Method 
All the reagents were obtained commercially of 
analytical grade and were used without further 
purification unless otherwise stated. The melting 
points were determined by open capillary method and 
are uncorrected. The Infrared (IR) spectra (KBr) were 
recorded on a Nicolet-5700 FT-IR spectrophotometer. 
1H NMR and 13C NMR spectra were recorded on 
Bruker 400 MHz spectrometer and Jeol 400 MHz 
using DMSO-d6, as solvent and tetramethylsilane 
 
 




Figure 8 — (A) Hydrophobic amino acids surrounded to compounds 6d (green color)and 6a (cyan color). (B) Hydrophilic amino acids
surrounded to compounds 6d and 6a 




(TMS) as an internal standard and the chemical shifts 
are expressed in ppm (δ-scale). The mass spectra were 
recorded using Agilent- single Quartz GC-MS. The Purity 
of compounds is checked by Thin Layer Chromatography 
(TLC) which was performed on Merck Silica Gel 60 
F254 and visualized under UV light chamber. 
General procedure for the synthesis of coumarin-
1,4-dihydropyridine, 6a-o 
A solution of dimethyl acetylenedicarboxylate 
(DMAD) (1.0 mmol,) and substituted aniline  
(1.0 mmol) was taken in round bottom flask and 
stirred for 4 h at RT. Meanwhile, substituted 4-
 
 




Figure 10 — Interaction of Ibuprofen at the binding site of the enzyme (PDB ID: 4PH9) 




formylcoumarin (1.0 mmol,) and malononitrile (1.0 
mmol,) in 2 mL of ethanol was added to it with 
catalytic amount of triethylamine and stirred the 
reaction mixture for another 8 h at RT. The reaction 
mixture was stirred until the reaction was completed 
and confirmed by TLC. After completion, the 
resulting precipitate was collected by filtration and 






2,3-dicarboxylate, 6a: The compound 6a obtained 
from 6-methyl-2-oxo-2H-chromene-4-carbaldehyde 
(1.0mmol), DMAD (1.0mmol), malononitrile 
(1.0mmol), aniline (1.0mmol). Yellow solid. Yield 
85%. m.p.268-270°C; IR (KBr): 3423, 2180, 1753 
and 1712 cm−1; 1H NMR (400 MHz, DMSO-d6):  
δ 2.41(s, 3H, C6-CH3 of coumarin), 3.35(s, 3H, -
OCH3 of ester), 3.45(s, 3H, -OCH3 of ester), 5.12(s, 
1H, CH of dihydropyridine), 5.84(s, 2H, NH2), 6.18(s, 
1H, C3-H of coumarin), 7.26(dd, 1H, J=9.2 Hz, J=2 
Hz, C7-H of coumarin), 7.25-7.27 (m, 3H, CH of 
phenyl ring), 7.49(s, 1H, C5-H of coumarin), 7.49-
7.50(m, 2H, CH of phenyl ring), 8.02 (d, 1H, J=8.4 
Hz, C8-H of coumarin);
 13C NMR (100 MHz, DMSO-
d6): δ 21.55 (C6-CH3), 33.73 (C4-CH of DHP), 52.75 
(OCH3 of ester), 53.14 (OCH3 of ester), 57.46, 
102.71, 111.80, 114.62, 115.65, 117.47 (CN), 120.88, 
125.66, 126.05, 130.33, 130.75, 135.04, 135.49, 
144.02, 144.17, 152.54, 154.24, 159.11, 159.49, 
161.10 (CO of coumarin), 163.13 (CO of ester), 




dropyridine-2,3-dicarboxylate, 6b: The compound 
6b obtained from 6-methyl-2-oxo-2H-chromene-4-
carbaldehyde (1.0mmol), DMAD (1.0mmol), 
malononitrile (1.0mmol), 3,4-dimethylamine 
(1.0mmol). Gray solid. Yield 87%. m.p.268-270°C; 
IR (KBr): 3413, 2185, 1750 and 1711 cm−1; 1H NMR 
(400 MHz, DMSO-d6): δ 2.28 (s, 6H, C3 and C4-CH3 
of phenyl ring), 2.45 (s, 3H, C6-CH3 of coumarin), 
3.47(s, 3H, -OCH3 of ester), 3.55(s, 3H, -OCH3 of 
ester), 4.24(s, 2H, NH2), 5.12(s, 1H, CH of 
dihydropyridine), 6.36(s, 1H, C3-H of coumarin), 
7.04(dd, 1H, J=8 Hz, J=2 Hz, C7-H of coumarin), 
7.07(s, 1H, C5-H of coumarin), 7.19(m, 3H, CH of 
phenyl ring), 7.91(d, 1H, J=8 Hz, C8-H of coumarin);
 
13C NMR (100 MHz, DMSO-d6): δ 19.74(C3- CH3 of 
phenyl), 19.86 ((C4- CH3 of phenyl)), 21.73(C6-CH3), 
32.87(C4-CH of DHP), 52.50(OCH3 of ester), 
52.88(OCH3 of ester), 59.15, 99.99, 102.43, 112.81, 
115.52, 117.55(CN), 120.13, 124.50, 125.77, 127.45, 
130.74, 131.15, 140.12, 143.66, 143.88, 151.36, 
153.11, 154.28, 158.61, 162.25(CO of coumarin), 
162.94(CO of ester), 164.83(CO of ester). Anal. 
Calcd for C28H25N3O6: C, 67.33; H, 5.04; N,  
8.41. Found: C, 67.36; H, 5.02; N, 8.44%. GC-MS: 




py ridine-2,3-dicarboxylate, 6c: The compound 6c 
obtained from 6-methyl-2-oxo-2H-chromene-4-
carbaldehyde (1.0mmol), DMAD (1.0mmol), 
malononitrile (1.0mmol), 4-chlorobenzenamine 
(1.0mmol). Gray solid. Yield 83%. m.p.252-254°C; 
IR (KBr): 3346, 2185, 1750 and 1700 cm−1; 1H NMR 
(400 MHz, DMSO-d6): δ 2.42 (s, 3H, C6-CH3 of 
coumarin), 3.43(s, 3H, -OCH3 of ester), 3.62(s, 3H, -
OCH3 of ester), 4.21(s, 2H, NH2), 5.21(s, 1H, CH of 
dihydropyridine), 6.23(s, 1H, C3-H of coumarin), 
7.15(dd, 1H, J = 8 Hz, J = 2 Hz, C7-H of coumarin), 
7.22(d, 1H, J=7.2 Hz, C5-H of coumarin), 7.27(d, 4H, 
J = 8 Hz, CH of phenyl ring), 7.87(d, 1H, J=8 Hz,  
C8-H of coumarin);
 13C NMR (100 MHz, DMSO-d6): 
δ 22.54(C6-CH3), 33.27(C4-CH of DHP), 51.91(OCH3 
of ester), 52.31(OCH3 of ester), 58.25, 100.19, 
105.23, 115.57, 117.02, 117.85(CN), 119.34, 123.21, 
125.37, 130.64, 132.27, 139.45, 141.27, 144.67, 
151.36, 155.04, 157.11, 161.24(CO of coumarin), 
163.17(CO of ester), 165.23(CO of ester). Anal. 
Calcd for C26H20ClN3O6: C, 61.73; H, 3.98; N, 8.31. 





2,3-dicarboxylate, 6d: The compound 6d obtained 
from 7-methyl-2-oxo-2H-chromene-4-carbaldehyde 
(1.0mmol), DMAD (1.0mmol), malononitrile 
(1.0mmol), aniline (1.0mmol). Cream solid. Yield 
86%. m.p.238-232°C; IR (KBr): 3432, 2178, 1749 
and 1710 cm−1; 1H NMR (400 MHz, DMSO-d6): δ 
2.35 (s, 3H, C7-CH3 of coumarin), 3.42(s, 3H, -OCH3 
of ester), 3.48(s, 3H, -OCH3 of ester), 5.18(s, 1H, CH 
of dihydropyridine), 5.64(s, 2H, NH2), 6.24(s, 1H, C3-
H of coumarin), 7.21(dd, 1H, J=8 Hz, J=2 Hz, C6-H 
of coumarin), 7.23-7.29(m, 3H, CH of phenyl ring), 




7.51(s, 1H, C8-H of coumarin), 7.52-7.55(m, 2H, CH 
of phenyl ring), 7.89(d, 1H, J=8.4 Hz, C5-H of 
coumarin); 13C NMR (100 MHz, DMSO-d6): δ 
23.13(C7-CH3), 35.02(C4-CH of DHP), 53.17(OCH3 
of ester), 54.35(OCH3 of ester), 56.08, 101.11, 
113.20, 113.87, 115.67, 116.46(CN), 119.14, 121.76, 
128.15, 131.47, 133.27, 135.19, 137.49, 142.49, 
143.07, 151.62, 155.17, 157.22, 158.45, 162.87(CO of 
coumarin), 163.72(CO of ester), 165.49(CO of ester). 
Anal. Calcd for C26H21N3O6: C, 66.24; H, 4.49; N, 
8.91. Found: C, 66.26; H, 4.48; N, 8.94%. GC-MS: 




dihydropyridine-2,3-dicarboxylate, 6e: The 
compound 6e obtained from 7-methyl-2-oxo-2H-
chromene-4-carbaldehyde (1.0mmol), DMAD 
(1.0mmol), malononitrile (1.0mmol), 3,4-
dimethylamine (1.0mmol). Gray solid. Yield 89%. 
m.p.222-224°C; IR (KBr): 3432, 2175, 1754 and  
1718 cm−1; 1H NMR (400 MHz, DMSO-d6): δ 2.28 (s, 
6H, C3 and C4-CH3 of phenyl ring), 2.45(s, 3H,  
C7-CH3 of coumarin), 3.48(s, 3H, -OCH3 of ester), 
3.57(s, 3H, -OCH3 of ester), 4.25(s, 2H, NH2), 5.12(s, 
1H, CH of dihydropyridine), 6.40(s, 1H, C3-H of 
coumarin), 7.05(d, 2H, J=8.4 Hz, CH of phenyl ring), 
7.22(d, 1H, J=8 Hz, C5-H of coumarin), 7.26(s, 1H, 
CH of phenyl ring), 7.37(d, 1H, J=8 Hz, C6-H of 
coumarin), 7.82 (s, 1H, C8-H of coumarin);
 13C NMR 
(100 MHz, DMSO-d6): δ19.74(C3- CH3 of phenyl), 
19.86(C4- CH3 of phenyl), 21.27, 32.89(C4-CH of 
DHP), 52.52(OCH3 of ester), 52.89(OCH3 of ester), 
59.03, 102.44, 113.79, 117.05(CN), 117.60, 120.10, 
124.81, 127.23, 130.75, 131.16, 131.83, 133.30, 
134.18, 139.20, 140.12, 143.90, 151.48, 152.31, 
158.21, 162.13(CO of coumarin), 162.94(CO of 
ester), 164.83(CO of ester). Anal. Calcd for 
C28H25N3O6: C, 67.33; H, 5.04; N, 8.41. Found: C, 




pyridine-2,3-dicarboxylate, 6f: The compound 6f 
obtained from 7-methyl-2-oxo-2H-chromene-4-
carbaldehyde (1.0mmol), DMAD (1.0mmol), 
malononitrile (1.0mmol), 4-chlorobenzamine 
(1.0mmol). White solid. Yield 78%. m.p.232-234°C; 
IR (KBr): 3438, 3337, 2277, 1748 and 1726 cm−1; 
1H NMR (400 MHz, DMSO-d6): δ 2.53 (s, 3H, C7-
CH3 of coumarin), 3.58(s, 3H, -OCH3 of ester), 3.62(s, 
3H, -OCH3 of ester), 4.19(s, 2H, NH2), 5.60(s,1H, CH 
of dihydropyridine), 6.26(s, 1H, C3-H of coumarin), 
7.35(d, 2H, J=7.8 Hz, C6-H of coumarin), 7.47(dd, 
3H, J=8.4 Hz, C5-H of coumarin), 7.82(d, 4H, J=8 
Hz, CH of phenyl ring), 8.23(s, 1H, C8-H of 
coumarin); 13C NMR (100 MHz, DMSO-d6): δ 20.83, 
45.64(C4-CH of DHP), 53.53(OCH3 of ester), 
54.65(OCH3 of ester), 61.30, 102.30, 105.23, 108.21, 
116.87, 118.10 (CN), 118.94, 120.07, 122.19, 125.43, 
129.63, 131.37, 134.03, 140.96, 143.27, 147.38, 
153.74, 156.34, 159.70, 160.29(CO of coumarin), 
163.06(CO of ester), 167.58(CO of ester). Anal. 
Calcd for C26H20ClN3O6: C, 61.73; H, 3.98; N, 8.31. 
Found: C, 61.75; H, 3.96; N, 8.35%. GC-MS:  




opyridine-2,3-dicarboxylate, 6g: The compound 6g 
obtained from 6-methoxy-2-oxo-2H-chromene-4-
carbaldehyde (1.0mmol), DMAD (1.0mmol), 
malononitrile (1.0mmol), 4-methoxybenzenamine 
(1.0mmol). Light yellow solid. Yield 78%. m.p.218-
220°C; IR (KBr): 3401, 3334, 2220, 1745 and 1725 
cm−1; 1H NMR (400 MHz, DMSO-d6): δ 3.49 (s, 3H, -
OCH3 of ester), 3.59 (s, 3H, -OCH3 of ester), 3.80 (s, 
6H, C6-OCH3 ), 5.03 (s, 1H, CH of dihydropyridine), 
5.76(s, 2H, NH2), 6.23(s, 1H, C3-H of coumarin), 
7.01-7.03(m, 2H, Ar-H), 7.24-7.32(m, 3H, Ar-H ), 
7.85 (t, 2H Ar-H). 13C NMR (100 MHz, DMSO-d6): δ 
23.13, 35.02(C4-CH of DHP), 53.17(OCH3 of ester), 
54.35(OCH3 of ester), 56.08, 101.11, 113.87, 115.67, 
116.46(CN), 119.14, 121.76, 124.43, 128.15, 131.47, 
133.27, 135.19, 137.49, 142.49, 143.07, 151.62, 
155.17, 157.22, 158.45, 160.37(CO of coumarin), 
163.72(CO of ester), 165.49(CO of ester). Anal. 
Calcd for C27H23N3O8: C, 62.67; H, 4.48; N, 8.12. 





1,4-dihyd ropyridine-2,3-dicarboxylate, 6h: The 
compound 6h obtained from 6-methoxy-2-oxo-2H-
chromene-4-carbaldehyde (1.0mmol), DMAD 
(1.0mmol), malononitrile (1.0mmol), 3,4-
dimethylamine (1.0mmol). Gray solid. Yield 84%. 
m.p.232-234°C; IR (KBr): 3431, 2179, 1748 and 1707 
cm−1; 1H NMR (400 MHz, DMSO-d6): δ 2.29(s, 6H, 
C3 and C4-CH3 of phenyl ring), 3.94(s, 3H, C6-OCH3 
of coumarin), 3.49(s, 3H, -OCH3 of ester), 3.59(s, 3H, 




-OCH3 of ester), 4.26(s, 2H, NH2), 5.08(s, 1H, CH of 
dihydropyridine), 6.42 (s, 1H, C3-H of coumarin), 
7.06(d, 2H, J=8 Hz, CH of phenyl ring), 7.21(s, 1H, 
CH of phenyl ring), 7.15(dd, 1H, J=8.8 Hz, J=2.8 Hz, 
C7-H of coumarin), 7.30(d, 1H, J=8.8 Hz, C8-H of 
coumarin), 7.47(d, 1H, J=2.8 Hz, C5-H of coumarin);
 
13C NMR (100 MHz, DMSO-d6): δ 19.74(C3- CH3 of 
phenyl), 19.86(C4- CH3 of phenyl), 21.27, 32.89(C4-
CH of DHP), 52.52(OCH3 of ester), 52.89(OCH3 of 
ester), 59.03, 102.44, 113.79, 117.05, 117.60(CN), 
120.10, 124.81, 127.23, 130.75, 131.16, 131.83, 
133.30, 134.18, 139.20, 140.12, 143.90, 151.48, 
152.31, 158.21, 162.13(CO of coumarin), 162.94(CO 
of ester), 164.83(CO of ester). Anal. Calcd for 
C28H25N3O7: C, 65.24; H, 4.89; N, 8.15. Found: C, 




dihydrop yridine-2,3-dicarboxylate, 6i: The 
compound 6i obtained from 6-methoxy-2-oxo-2H-
chromene-4-carbaldehyde (1.0mmol), DMAD 
(1.0mmol), malononitrile (1.0mmol), 4-
chlorobenzamine (1.0mmol). Gray solid. Yield 82%. 
m.p.230-232°C; IR (KBr): 3414, 3334, 2219, 1748 
and 1726 cm−1; 1H NMR (400 MHz, DMSO-d6): δ 
3.71(s, 3H, -OCH3 of ester), 3.73(s, 3H, -OCH3 of 
ester), 3.88(s, 3H, C6-OCH3 of coumarin), 4.27(s, 2H, 
NH2), 5.21(s, 1H, CH of dihydropyridine), 6.14(s, 1H, 
C3-H of coumarin), 7.10(t, 2H, J=8.7 and Hz, J= 8.5 
Hz, Ar-H), 7.19(m, 3H,Ar-H), 7.29(d, 2H, J =4.2 Hz, 
Ar-H), 7.80(d, 1H, J= 8.6Hz, Ar-H); 13C NMR (100 
MHz, DMSO-d6): δ 22.19, 47.06(C4-CH of DHP), 
52.37(OCH3 of ester), 55.73(OCH3 of ester), 
60.01,100.30, 105.77, 110.16, 117.34, 117.90(CN), 
119.46, 121.03, 123.00, 127.88, 130.63, 132.07, 
136.47, 142.23, 145.82, 150.18, 155.04, 157.38, 
159.64, 162.86(CO of coumarin), 165.67(CO of 
ester), 169.78(CO of ester). Anal. Calcd for 
C26H20ClN3O7: C, 59.83; H, 3.86; N, 8.05. Found: C, 




dicarboxylate, 6j: The compound 6j obtained from 3-
oxo-3H-benzo[f]chromene-1-carbaldehyde1.0mmol), 
DMAD (1.0mmol), malononitrile (1.0mmol), aniline 
(1.0mmol). Pink solid. Yield 74%. m.p.247-249°C; IR 
(KBr): 3393, 2219, 1732 and 1695 cm−1; 1H NMR 
(400 MHz, DMSO-d6): δ 3.67(s, 3H, -OCH3 of ester), 
3.93(s, 3H, -OCH3 of ester), 4.32(s, 1H, CH of 
dihydropyridine), 5.18(s, 2H, NH2), 6.00(s, 1H, C3-H 
of coumarin), 7.60-6.70(m, 5H, of phenyl ring), 
7.80(dd, 2H, J=8.4 Hz, J=1.2 Hz, C6 and C7-H of 
coumarin), 8.11(d, 2H, J=7.2 Hz, C9 and C10-H of 
coumarin), 8.29(d, 1H, J=8.8Hz, C5-H of coumarin), 
8.65(d, 1H, J=8.4 Hz, C8-H of coumarin);
 13C NMR 
(100 MHz, DMSO-d6): δ 37.14(C4-CH of DHP), 
53.66(OCH3 of ester), 56.09(OCH3 of ester), 57.34, 
113., 115.33, 117.94(CN), 120.54, 121.39, 123.77, 
124.84, 125.76, 126.29, 126.73, 129.23, 130.62, 
131.49, 134.68, 139.67, 141.77, 144.00, 153.16, 
155.23, 157.01, 159.42, 160.72(CO of coumarin), 
161.97, 162.04(CO of ester), 163.88(CO of ester). 
Anal. Calcd for C29H21N3O6: C, 68.63; H, 4.17; N, 
8.28. Found: C, 68.68; H, 4.15; N, 8.31%. GC-MS: 




ropyridine-2,3-dicarboxylate, 6k: The compound 6k 
obtained from 3-oxo-3H-benzo[f]chromene-1-
carbaldehyde1.0mmol), DMAD (1.0mmol), 
malononitrile (1.0mmol), 3,4-dimethylamine 
(1.0mmol). Pink solid. Yield 76%. m.p.248-250°C; IR 
(KBr): 3426, 3337, 2225, 1746 and 1726 cm−1; 
1H NMR (400 MHz, DMSO-d6): δ 2.38 and 2.43 (s, 
6H, C3 and C4-CH3 of phenyl ring), 3.53(s, 3H, -
OCH3 of ester), 3.65(s, 3H, -OCH3 of ester), 4.78(s, 
2H, NH2), 5.19(s,1H, 1H, CH of dihydropyridine), 
6.21(s, 1H, C3-H of coumarin), 7.31(d, 1H, Ar-H, 
J=8.0 Hz), 7.43(t, 2H, Ar-H), 7.67(m, 4H, Ar-H), 
7.64(t, 1H, Ar-H), 7.72(d, 2H, J=6.4 Hz, Ar-H), 
7.91(s, 1H, Ar-H), 8.04(d, 1H, J=4 Hz, Ar-H); 
13C NMR (100 MHz, DMSO-d6): δ 22.76(C3- CH3 of 
phenyl), 23.17(C4- CH3 of phenyl), 36.12(C4-CH of 
DHP), 54.03(OCH3 of ester), 55.43(OCH3 of ester), 
57.18, 100.26, 111.45, 112.19, 114.34, 117.44(CN), 
118.69, 122.31, 123.08, 124.77, 126.25, 129.11, 
130.37, 134.18, 137.02, 137.46, 140.76, 142.83, 
152.81, 155.27, 155.92, 157.94, 159.42, 161.53(CO of 
coumarin), 162.89(CO of ester), 165.75(CO of ester). 
Anal. Calcd for C31H25N3O6: C, 69.52; H, 4.71; N, 
7.85. Found: C, 69.58; H, 4.65; N, 7.87%. GC-MS: 




yridine-2,3-dicarboxylate, 6l: The compound 6l 
obtained from 3-oxo-3H-benzo[f]chromene-1-
carbaldehyde10.0mmol), DMAD (1.0mmol), 
malononitrile (1.0mmol), 4-chloroaniline (1.0mmol). 




Pink solid. Yield 75%. m.p.246-248°C; IR (KBr): 
3398, 2198, 1742 and 1724 cm−1; 1H NMR (400 
MHz, DMSO-d6): δ 3.59(s, 3H, -OCH3 of ester), 
3.91(s, 3H, -OCH3 of ester), 4.23(s, 1H, CH of 
dihydropyridine), 5.18(s, 2H, NH2), 5.67(s, 1H, C3-H 
of coumarin), 6.63 (d, 2H, J=7.2 Hz, CH of phenyl 
ring), 6.96 (d, 2H, J=7.2 Hz, CH of phenyl ring), 
7.53-7.74(m, 4H, of coumarin), 8.09 (d, 1H, J=8.4 
Hz, C5-H of coumarin), 8.28(d, 1H, J=9.2 Hz, C9-H of 
coumarin); 13C NMR (100 MHz, DMSO-d6): δ 
32.93(C4-CH of DHP), 54.17(OCH3 of ester), 
54.66(OCH3 of ester), 56.23, 112.11, 112.87, 113.22, 
114.37, 117.29(CN), 118.33, 122.41, 122.89, 123.54, 
125.02, 127.45, 130.00, 131.24, 133.49, 135.62, 
139.88, 142.17, 152.84, 154.31, 155.03, 158.15, 
159.28, 161.94(CO of coumarin), 164.68(CO of 
ester), 165.49(CO of ester). Anal. Calcd for 
C29H20ClN3O6: C, 64.27; H, 3.72; N, 7.75. Found: C, 




2,3-dicarboxylate, 6m: The compound 6m obtained 
from 2-oxo-2H-benzo[h]chromene-4-carbaldehyde 
(1.0mmol), DMAD (1.0mmol), malononitrile 
(1.0mmol), aniline (1.0mmol). Gray solid. Yield 74%. 
m.p.247-249°C; IR (KBr): 3464, 2182, 1751 and 1708 
cm−1; 1H NMR (400 MHz, DMSO-d6): δ 3.36(s, 3H, -
OCH3 of ester), 3.43(s, 3H, -OCH3 of ester), 4.31(s, 
1H, CH of dihydropyridine), 5.30(s, 2H, NH2), 6.35(s, 
1H, C3-H of coumarin), 7.49-6.54 (m, 5H, of phenyl 
ring), 7.26-7.30 (m, 2H, of coumarin), 7.71-7.74 (m, 
2H, of coumarin), 7.95(d, 1H, J=8.8 Hz, C9-H of 
coumarin), 8.65 (d, 1H, J=9.2 Hz, C5-H of coumarin);
 
13C NMR (100 MHz, DMSO-d6): δ 35.14(C4-CH of 
DHP), 52.74, 53.15(OCH3 of ester), 56.54(OCH3 of 
ester), 100.39, 102.84, 113.38, 114.63, 117.45(CN), 
120.87, 121.61, 122.34, 122.92, 127.11, 129.28, 
130.72, 133.77, 135.22, 138.45, 140.78, 141.21, 
151.09, 152.51, 154.77, 158.45, 160.37, 162.87(CO of 
coumarin), 163.62(CO of ester), 164.94(CO of ester). 
Anal. Calcd for C29H21N3O6: C, 68.63; H, 4.17; N, 
8.28. Found: C, 68.69; H, 4.15; N, 8.30%. GC-MS: 
m/z 507 (M+). 
 
Dimethyl 6-amino-5-cyano-1-(3,4-dimeth ylphe 
nyl)-4-(2-oxo-2H-benzo[h]chromen-4-yl)-1,4-dihy 
dropyridine-2,3-dicarboxylate, 6n: The compound 
6n obtained from 2-oxo-2H-benzo[h]chromene-4-
carbaldehyde (1.0mmol), DMAD (1.0mmol), 
malononitrile (1.0mmol), 3,4-dimethylamine 
(1.0mmol). Gray solid. Yield 74%. m.p.247-249°C; 
IR (KBr): 3428, 3338, 2260, 1755 and 1728 cm−1; 
1H NMR (400 MHz, DMSO-d6): δ 2.38(s, 3H, C3-CH3 
of phenyl ring), 2.49(s, 3H, C4-CH3 of phenyl ring), 
3.53(s, 3H, -OCH3 of ester), 3.54(s, 3H, -OCH3 of 
ester), 5.28(s, 1H, CH of dihydropyridine), 5.49 (s, 
2H, NH2), 6.36(s, 1H, C3-H of coumarin), 6.65(d, 1H, 
J = 8Hz, Ar-H), 6.97(d, 1H, J = 8Hz, Ar-H), 7.12(t, 
2H, Ar-H), 7.72-7.30(m, 3H, Ar-H), 7.38(s, 1H,Ar-
H), 7.96(d. 1H, J=8 Hz, Ar-H); 13C NMR (100 MHz, 
DMSO-d6): δ 19.12(C3- CH3 of phenyl), 19.84(C4- 
CH3 of phenyl), 35.17(C4-CH of DHP), 53.3(OCH3 
of ester), 54.17(OCH3 of ester), 57.22, 100.42, 
111.01, 113.44, 115.00, 117.26(CN), 120.54, 122.67, 
123.49, 124.93, 128.11, 128.75, 130.57, 131.84, 
136.27, 139.19, 141.97, 144.58, 150.39, 154.69, 
156.12, 159.01, 161.21, 161.94(CO of coumarin), 
162.17(CO of ester), 164.94(CO of ester). Anal. 
Calcd for C31H25N3O6: C, 69.52; H, 4.71; N,  
7.85. Found: C, 69.56; H, 4.67; N, 7.87%. GC-MS: 




pyridine-2,3-dicarboxylate, 6o: The compound 6o 
obtained from 2-oxo-2H-benzo[h]chromene-4-
carbaldehyde (1.0 mmol), DMAD (1.0 mmol), 
malononitrile (1.0 mmol), 4-chloroaniline (1.0 mmol). 
Gray solid. Yield 75%. m.p.247-249°C; IR (KBr): 
3439, 3320, 2232, 1743 and 1722cm−1; 1H NMR (400 
MHz, DMSO-d6): δ 3.37(s, 3H, -OCH3 of ester), 
3.45(s, 3H, -OCH3 of ester), 5.18(s, 1H, CH of 
dihydropyridine), 5.42(s, 2H, NH2), 6.37(s, 1H, C3-H 
of coumarin), 6.91(d, 1H, J = 8.0 Hz, Ar-H ), 7.32(d, 
1H, J = 8.0 Hz, Ar-H), 7.41(d, 1H, J = 4.0 Hz, Ar-H ), 
7.48(d, 1H, J =8 Hz, Ar-H), 7.56(d, 3H, J = 12Hz, Ar-
H ), 7.78 (m, 2H, Ar-H) 8.29(d,1H, J=8.0 Hz, Ar-H); 
13C NMR (100 MHz, DMSO-d6): δ 35.07(C4-CH of 
DHP), 53.38(OCH3 of ester), 54.12(OCH3 of ester), 
56.47, 101.01, 111.80, 113.25, 116.00, 116.76(CN), 
119.37, 122.16, 125.17, 125.84, 126.46, 127.35, 
130.49, 133.17, 135.27, 139.23, 141.78, 142.48, 
152.07, 155.89, 157.45, 159.46, 160.11, 161.83(CO of 
coumarin), 162.54(CO of ester), 164.92(CO of ester). 
Anal. Calcd for C29H20ClN3O6: C, 64.27; H, 3.72; N, 
7.75. Found: C, 64.31; H, 3.70; N, 7.76%. GC-MS: 
m/z 541 (M+). 
 
Conclusions 
In summary, we have, synthesized novel coumarin-
1,4-dihydropyridines via one pot multicomponent 




reaction by using activated alkyl and active methylene 
compound at environmentally friendly reaction 
condition, with easy workup and time saving. All the 
compounds are found to be good to moderate 
antimicrobial agent, wherein compounds 6a, 6e and 
6n are found low MIC value 32 µM/mL and these are 
considered to be prime candidate for further 
development of new class of antibacterial agents. The 
synthesized novel dihydropyridines exhibited as 
significant anti-inflammatory activity, among all 
compound 6i is found to be highly promising anti-
inflammatory agent. Molecular docking study was 
performed for all the dihydropyridine derivatives with 
S. aureus DNA gyrase andcyclooxygenase-2 (PDB ID 
4PH9).Compounds 6a and 6d showed better bonding 
interaction againstDNA gyrase whereas, compounds 
6d and 6e found excellent interaction with 
cyclooxygenase-2 at the active site of the enzyme with 
maximum CScore value, while all other compounds 
results obtained were quite promising. 
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C NMR spectra 
and elemental analysis are available in the website 
http://nopr.niscair.res.i n/handle/12345678 9/60. 
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